540 related articles for article (PubMed ID: 31706583)
21. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
Saith SE; Maurer MS; Patel AR
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
[TBL] [Abstract][Full Text] [Related]
22. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Weiss BM; Wong SW; Comenzo RL
Blood; 2016 May; 127(19):2275-80. PubMed ID: 26907632
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin Light Chain Systemic Amyloidosis.
Dispenzieri A; Merlini G
Cancer Treat Res; 2016; 169():273-318. PubMed ID: 27696268
[TBL] [Abstract][Full Text] [Related]
24. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Parrondo RD; Majeed U; Sher T
Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
26. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
29. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy.
Cohen AD; Comenzo RL
Hematology Am Soc Hematol Educ Program; 2010; 2010():287-94. PubMed ID: 21239808
[TBL] [Abstract][Full Text] [Related]
30. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
[TBL] [Abstract][Full Text] [Related]
31. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
32. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis.
Schwotzer R; Flammer AJ; Gerull S; Pabst T; Arosio P; Averaimo M; Bacher VU; Bode P; Cavalli A; Concoluci A; Dirnhofer S; Djerbi N; Dobner SW; Fehr T; Garofalo M; Gaspert A; Heimgartner R; Hübers A; Jung HH; Kessler C; Knöpfel R; Laptseva N; Manka R; Mazzucchelli L; Meyer M; Mihaylova V; Monney P; Mylonas A; Nkoulou R; Pazhenkottil A; Pfister O; Rüfer A; Schmidt A; Seeger H; Stämpfli SF; Stirnimann G; Suter T; Théaudin M; Treglia G; Tzankov A; Vetter F; Zweier M; Gerber B
Swiss Med Wkly; 2020 Nov; 150():w20364. PubMed ID: 33277911
[TBL] [Abstract][Full Text] [Related]
33. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
Basset M; Nuvolone M; Palladini G; Merlini G
Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
[TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
35. Future directions in the clinical management of amyloid light-chain amyloidosis.
Haider S; Ahmad N; Anaissie E; Driscoll JJ
Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
[TBL] [Abstract][Full Text] [Related]
36. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
37. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
39. [AL amyloidosis].
Jaccard A; Desport E; Mohty D; Bridoux F
Rev Med Interne; 2015 Feb; 36(2):89-97. PubMed ID: 25194219
[TBL] [Abstract][Full Text] [Related]
40. [Light chain amyloidosis].
Hegenbart U; Aus dem Siepen F; Schönland S
Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
